medigraphic.com

2007, Number 6

<< Back

Rev Med Inst Mex Seguro Soc 2007; 45 (6)

Complaints for Treatment of Uterine Myomatosis

Fernández del Castillo-Sánchez C, Campos-Castolo EM, Sánchez-González JM, Santibáñez-Moreno G, Mancera-Reséndiz MÁ, Tena-Tamayo C

Language: Spanish
References: 57
Page: 629-638
PDF size: 181.21 Kb.


ABSTRACT

Complaints related to uterine myomatosis treatments received by the National Comission of Medical Arbitration (Conamed) between 2001 and 2005 were analyzed. Complaints were from patients affiliated to social security institutions (51.7%), private providers (34.5%) and public health care services (13.8%). A medical doctor suggested to fill in the complaint in 10.3% of cases. Perception of inadequate treatment was the most frequent cause (69%), incomplete medical charts were 60.3% and only 24% included the informed consent form. Medical information given to patients and relatives was inadequate (48.2%). Hysterectomy was performed to 84.5% of patients. The most frequent surgical complications were hemorrhage (25.7%), urologic injuries (25.7%) and surgical infections (12.7%). 36.4% of cases had no surgical complication. Main sequelae were: elapsed length of hospital stay (15%) and loss of an organ (other than uterus) or function (not reproductive) (13.8%). There was one death (1.7%). Medical malpractice was found in 29.3% of cases. Principal deviations: communication problems (29.6%), unjustified delayed surgery (29.4%) and delayed diagnosis of complications due to poor post-surgical care or premature hospital discharge (29.4%).


REFERENCES

  1. Sociedad Española de Ginecología y Obstetricia. Miomatosis uterina. Documentos de Consenso SEGO. Disponible en http://www.schering.es/varios/publicaciones /documentos_de_consenso_SEGO/html/consenso98/miomatosis.htm

  2. Spellacy WN. Leiomioma uterino. En: Scout JR, Di-Saia PJ, Hammond ChB, Spellacy WN, editors. Tratado de obstetricia y ginecología. 8ª ed. México: McGraw-Hill Interamericana; 2000.

  3. Cook JD, Walker CL. Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin Reprod Med 2004;22(2):105-111.

  4. Berek JS. Ginecología de Novak. 13ª ed. México: McGraw-Hill Interamericana; 2004.

  5. Stewart EA, Morton CC. The genetics of uterine leiomyomata: what clinicians need to know. Obstet Gynecol 2006;107(4):917-921.

  6. Kumar V, Robbins SL. Patología estructural y funcional. Aparato genital femenino. 7a ed. México: McGraw-Hill Interamericana; 2005.

  7. Committee on Patient Education of the American Collage of Obstetricians and Gynecologyst. Uterine fibroids. ACOG Patient Education Pamphlet. February 2005. 12345/98765.

  8. Hospital General de México (HGM). Miomatosis uterina. Guías diagnósticas del HGM. Disponible en http://hgm.salud.gob.mx/servmed/u_general_guias_5a.html.

  9. Ahued-Ahued JR, Fernández del Castillo C. Obstetricia y ginecología aplicadas. 2ª ed. México: El Manual Moderno; 2003.

  10. Guerrero CD. Hace 55 años: Terapéutica médica y quirúrgica del mioma uterino. Ginecol Obstet Mex 2001;69(12):492-499. Disponible en http://scielo-mx.bvs.br/scielo.php? script = sci_arttext&pid= S0300-9041200100 1200006&lng = es&nrm= iso>. ISSN 0300-9041.

  11. De Cherney AH, Pernoll MK. Diagnóstico y tratamiento ginecoobstétricos. 8ª ed. México: El Manual Moderno; p. 3-6.

  12. ACOG. Treatment of uterine leiomyomas. ACOG UptoDate in Obstetrics, Gynecology and Womens’ Health. Washington DC, USA: ACOG; 2005.

  13. Farquhar C, Arroll B, Ekeroma A, Fentiman G, Lethaby A, Rademaker L, et al. Working Party of the New Zealand Guidelines Group. An evidencebased guideline for the management of uterine fibroids. Aust N Z J Obstet Gynaecol 2001;41(2): 125-140.

  14. ACOG. Surgical alternatives to hysterectomy in the management of leiomyomas. ACOG practice bulletin

  15. Washington DC, USA: ACOG; 2000.

  16. Walker ChL, Stewart EA. Uterine fibroids: the elephant in the room. Science 308 (5728): 1589-1592. Disponible en http://stke.sciencemag.org/cgi/content/abstract/sci;308/5728/1589.

  17. De-Leo V, Morgante G, La Marca A, Musacchio MC, Sorace M, et al. A benefit-risk assessment of medical treatment for uterine leiomyomas. Drug Safety 2002;25(11):759-779.

  18. Steinawer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103:1331.

  19. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. The Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD002126.DOI: 10.1002/14651858.CD002126.pub2. Disponible en http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002126/frame.html.

  20. Johnson N, Barlow D, Lethaby A, Tavender E, Curr E, Garry R. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003677. Disponible en http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003677/frame.html

  21. Foulot H, Chopin N, Malartic C, Fauconnier A, Chapron C. Miomectomía por laparotomía. EMC, Techniques chirurgicales. Gynécologie. París, Francia: Elsevier SAS; 2005. p. 41-662.

  22. Agostini A, Colette E, Rponda I, Bretelle F, Cravello L, Blanc B. Miomectomía por vía vaginal. EMC, Techniques chirurgicales. Gynécologie. París, Francia: Elsevier SAS; 2005. p. 41-662.

  23. Lethaby A, Ivanova V, Johnson NP. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev. 2006; Apr 19;(2):CD003677. Disponible en http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003677/frame.html

  24. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006 Apr 19; (2):CD003855. Disponible en http://www.mrw.interscience.wiley. com/cochrane/clsysrev/articles/CD003855/frame.html.

  25. Conde-Agudelo A. Intrafascial abdominal hysterectomy: outcomes and complications of 867 operations. Int J Gynaecol Obstet 2000;68(3):233-239.

  26. Thompson JD, Rock JA, Ginecología quirúrgica. 9ª ed. México: Médica Panamericana; 2003.

  27. Visvanathan D, Connell R, Hall-Craggs MA, Cutner AS, Bown SG. Interstitial laser photocoagulation for uterine myomas. Am J Obstet Gynecol 2002;187:382-384.

  28. Bachmann G. Expanding treatment options for women with symptomatic uterine leiomyomas: timely medical breakthroughs. Fertil Steril 2006; 85(1):46-47.

  29. Gupta JK, Sinha AS, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. The Cochrane Database of System atic Reviews 2006, Issue 1. Art. No.: CD005073. DOI: 10.1002/14651858.CD005073.pub2. Disponible en http://www.mrw.interscience.wiley. com/cochrane/clsysrev/articles/CD005073/ frame.html.

  30. Goldbert J, Pereira L, Berghella V, Diamond J, Darai E, Seinera P, et al. Pregnancy outcomes alter treatment for fibromyomata: uterine artery embolization versus laparoscopic myomectomy. Am J Obstet Gynecol 2004;191:18-21.

  31. Cowan BD. Myomectomy and MRI-directed cryotherapy. Semin Reprod Med 2004;22(2):143-148.

  32. Celik H, Sapmaz E. Use of a single preoperative dose of misoprostol is efficacious for patients who undergo abdominal myomectomy. Fertil Steril 2003:79:1207-1210.

  33. Ginsburg ES, Benso CB, Garfield JM, Gleason RE, Friedman AJ. The effect of operative technique and uterine size on blood loss during myomectomy: a prospective randomized study. Fertil Steril 1993; 60: 956-962.

  34. Benecke C, Kruger TF, Siebert TI, Van-der-Merwe JP, Steyn DW. Effect of fibroids on fertility in patients undergoing assisted reproduction. A structured literature review. Gynecol Obstet Invest 2005;59(4):225-230.

  35. Severo-Ochoa LH [España]. Ginecología y atención primaria: problemas clínicos. Disponible en http://www.schering.es /varios/publicaciones/ginecologiayatencionprim/ginecologiayatencionprim.pdf.

  36. Jacoby AF. Uterine fibroids asociated to adverse obstetric outcomes. Obstet Gynecol 2006;107: 376-382.

  37. Exacoutos C, Rosati A. Ultrasound diagnosis of uterine myomas and complications in pregnancy. Obstet Gynaecol 1993;82(1):97-101.

  38. Bañuelos AR. Miomatosis uterina, un enfoque endocrinológico. Rev Endocrinol Nutr 2000;8(3):94-99.

  39. Qidwai GI, Caughey AB, Jacoby AF. Obstetric outcomes in women with sonographically identified uterine leiomyomata. Obstet Gynecol 2006; 107:376-382.

  40. Rosseti A, Sizzie O, Soranna L, Cucinelli F, Mancuso S, Lanzaone A. Long term results of laparoscopic myomectomy: recurrence rate in comparison with abdominal myomectomy. Hum Reprod 2001;16:770-774.

  41. Petersen FA. Foro Conmemorativo del XX Aniversario FUNSALUD “La salud de los mexicanos en el siglo XXI”. Disponible en http://xxaniversario. funsalud.org.mx/index.php/info/content/download/311/1112/file/Alfonso_Petersen_ Farah.pdf.

  42. Wynia MK. Performance measures for ethics quality. Effective Clin Pract 1999;2:294-299. Disponible en http://www.acponline.org/journals/ecp/novdec99/wynia.htm.

  43. Brennan T, Horwitz RI, Duffy FD, Cassel CK, Goode LD, Lipner RS. The role of physician specialty board certification status in the quality movement. JAMA 2004; 292:1038-1043.

  44. PAHO. Patients pledge to fight medical errors throughout the Americas. First regional workshop on patients for patient safety held in San Francisco. Disponible en http://www.who. int/patientsafety/events/06/PAHO_pressrelease_may06.pdf.

  45. Vargas-Hernández VM. Leiomiomatosis uterina, la histerectomía no siempre es la mejor opción. Rev HJ Mex 1996;63(3):57-60.

  46. Guerrero GML, et al. Embolización de miomas uterinos. Alternativa no quirúrgica para su control. Técnica e indicaciones. An Radiol Mex 2003;4:213-218.

  47. Showstack J, Lin F, Learman LA, Vittinghoff E, Kuppermann M, Varner RE, et al. Ms Research Group. A prospective study of 3 years of outcomes after hysterectomy with and without oophorectomy. Am J Obstet Gynecol 2006;194:711-717.

  48. Morales-Ramírez JJ, Sauceda-González LF. La mayoría de las quejas por atención ginecológica y obstétrica se generan por percepciones derivadas de resultados inevitables. Ginec Obstet Mex 2001;69:108-117.

  49. Institute of Medicine (U.S.). To err is human: building a safer health system. Washington, DC, USA: National Academy Press; 2000.

  50. Elder NC, Hickner J. Missing clinical information: the system is down. JAMA 2005;293:617-619.

  51. Pearlman MD, Gluck, PA. Medical liability and patient safety: setting the proper course. Obstet Gynecol 2005;105(5, Part 1):941-943.

  52. Tena-Tamayo C, Sotelo J. Malpractice in Mexico: arbitration not litigation. BMJ, 2005;331: 448-451.

  53. Tena-Tamayo C, Sánchez-González JM. Génesis del conflicto médico-paciente. Rev Soc Mex Admin Inst Salud 2005; 1(1):13-17.

  54. Peipert JF, Weitzen S, Cruickshank C, Story E, Ethridge D, Lapane K. Risk factors for febrile morbidity after hysterectomy. Obstet Gynecol 2004;103(1):86-91.

  55. Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003;79(5):1194-1198.

  56. Hernández RFA, De los Santos RH. Efecto de la histerectomía en la funcionalidad conyugal. RESPYN 2002;5. Disponible en http://www.respyn.uanl.mx/especiales/fororegional/051.htm.

  57. Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981;36(4):433-445.




2020     |     www.medigraphic.com